tbuckley/cabot-search huggingface dataset:
Integrated multi-omics profiling to dissect the spatiotemporal evolution of metastatic hepatocellular carcinoma
Authors: Yunfan Sun, Pin Wu, Zefan Zhang, Zejian Wang, Kaiqian Zhou, Minfang Song, Yuan Ji, Fenglin Zang, Limu Lou, Keqiang Rao, Pengxiang Wang, Yutong Gu, Jie Gu, Binbin Lu, Limeng Chen, Xiuqi Pan, Xiaojing Zhao, Lihua Peng, Dongbing Liu, Xiaofang Chen, Kui Wu, Penghui Lin, Liang Wu, Yulin Su, Min Du, Yingyong Hou, Xinrong Yang, Shuangjian Qiu, Yinghong Shi, Huichuan Sun, Jian Zhou, Xingxu Huang, David H. Peng, Liye Zhang, Jia Fan
Journal: Cancer Cell (2023)
ChREBP is activated by reductive stress and mediates GCKR-associated metabolic traits
Authors: Charandeep Singh, Byungchang Jin, Nirajan Shrestha, Andrew L. Markhard, Apekshya Panda, Sarah E. Calvo, Amy Deik, Xingxiu Pan, Austin L. Zuckerman, Amel Ben Saad, Kathleen E. Corey, Julia Sjoquist, Stephanie Osganian, Roya AminiTabrizi, Eugene P. Rhee, Hardik Shah, Olga Goldberger, Alan C. Mullen, Valentin Cracan, Clary B. Clish, Vamsi K. Mootha, Russell P. Goodman
Journal: Cell Metabolism (2023)
Early kinetics of C reactive protein for cancer-agnostic prediction of therapy response and mortality in patients treated with immune checkpoint inhibitors: a multicenter cohort study
Authors: Dominik A Barth, Florian Moik, Sarah Steinlechner, Florian Posch, Marie-Christina Mayer, Amelie M Sandner, Franziska Berton, Verena Schlintl, Lukas Koch, Nikolaus John, Robert Wurm, Martin Pichler, Thomas Bauernhofer, Patrick Reimann, Christoph Wohlkönig, Erika Richtig, Thomas Winder, Matthias Preusser, Philipp J Jost, Cihan Ay, Armin Gerger, Angelika Terbuch, Jakob Michael Riedl
Journal: Journal for ImmunoTherapy of Cancer (2023)

Background C reactive protein (CRP) kinetics have recently been suggested as predictive biomarkers for the efficacy of immune checkpoint inhibitor (ICI) therapy in selected cancer types. The aim of this study was to characterize early CRP kinetics as a tumor-agnostic biomarker for ICI treatment outcomes. Methods In this multicenter retrospective cohort study, two independent cohorts of patients with various cancer types undergoing palliative ICI treatment at Austrian academic centers served as the discovery (n=562) and validation cohort (n=474). Four different patterns of CRP kinetics in the first 3 months of ICI therapy were defined (CRP-flare responders, CRP-responders, CRP non-responders, patients with all-normal CRP). Objective response rate (ORR), progression-free survival (PFS) and overall survival (OS) were defined as coprimary endpoints. Univariable and multivariable logistic regression, landmark analysis and Cox regression including CRP kinetics as time-dependent variable were performed. Results The ORR in patients with all-normal CRP, CRP responders, CRP flare-responders and CRP non-responders was 41%, 38%, 31% and 12%, respectively. The median OS and PFS estimates were 24.5 months (95% CI 18.5 to not reached) and 8.2 months (95% CI 5.9 to 12.0) in patients with all-normal CRP, 16.1 months (95% CI 12.6 to 19-8) and 6.1 months (95% CI 4.9 to 7.2) in CRP-responders, 14.0 months (95% CI 8.5 to 19.4) and 5.7 months (95% CI 4.1 to 8.5) in CRP flare-responders and 8.1 months (95% CI 5.8 to 9.9) and 2.3 months (95% CI 2.2 to 2.8) in CRP non-responders (log-rank p for PFS and OS&lt;0.001). These findings prevailed in multivariable analysis and could be fully confirmed in our validation cohort. Pooled subgroup analysis suggested a consistent predictive significance of early CRP kinetics for treatment efficacy and outcome independent of cancer type. Conclusion Early CRP kinetics represent a tumor-agnostic predictor for treatment response, progression risk and mortality in patients with cancer undergoing ICI therapy.
Phenotypic and genotypic antimicrobial resistance of Listeria monocytogenes: an observational study in France
Authors: Alexandra Moura, Alexandre Leclercq, Guillaume Vales, Nathalie Tessaud-Rita, Hélène Bracq-Dieye, Pierre Thouvenot, Yoann Madec, Caroline Charlier, Marc Lecuit
Journal: The Lancet Regional Health - Europe (2023)

Large-scale studies are needed to clarify antimicrobial resistance in the foodborne pathogen
Amphotericin B-loaded natural latex dressing for treating Candida albicans wound infections using Galleria mellonella model
Authors: Rondinelli Donizetti Herculano, Camila Eugênia dos Reis, Silvia Maria Batista de Souza, Giovana Sant'Ana Pegorin Brasil, Mateus Scontri, Satoru Kawakita, Bruna Gregatti Carvalho, Camila Calderan Bebber, Yanjin Su, Ana Paula de Sousa Abreu, Marvin M Mecwan, Kalpana Mandal, Ana Marisa Fusco Almeida, Maria José Soares Mendes Giannini, Nayrim Brizuela Guerra, Cassamo Ussemane Mussagy, Maria Rachel Melo Bosculo, José Lúcio Pádua Gemeinder, Breno Fernando Martins de Almeida, Juliana Ferreira Floriano, Neda Farhadi, Mahsa Monirizad, Danial Khorsandi, Huu Tuan Nguyen, Alejandro Gomez, Zuzana Tirpáková, Arne Peirsman, Josana Carla da Silva Sasaki, Siqi He, Samuel Forster, Betina Sayeg Burd, Mehmet Remzi Dokmeci, Maíra Terra-Garcia, Juliana Campos Junqueira, Ricardo José de Mendonça, Marcos Roberto Cardoso, Lindomar Soares dos Santos, Gláucio Ribeiro Silva, Natan Roberto Barros, Vadim Jucaud, Bingbing Li
Journal: Journal of Controlled Release (2023)
Injectable dexamethasone-loaded peptide hydrogel for therapy of radiation-induced ototoxicity by regulating the mTOR signaling pathway
Authors: Jingyu Liu, Lisheng Zhu, Yuqing Bao, Zhouyuan Du, Liangliang Shi, Xiaohua Hong, Zhenwei Zou, Gang Peng
Journal: Journal of Controlled Release (2023)

Radiation-induced ototoxicity is associated with inflammation response and excessive reactive oxygen species in the cochlea. However, the effectiveness of many drugs in clinical settings is limited due to anatomical barriers in the inner ear and pharmacokinetic instability. To address this issue, we developed an injectable hydrogel called RADA
Robust and fast stochastic 4D flow vector-field signature technique for quantifying composite flow dynamics from 4D flow MRI: Application to left atrial flow in atrial fibrillation
Authors: Thara Nallamothu, Maurice Pradella, Michael Markl, Philip Greenland, Rod Passman, Mohammed Sm Elbaz
Journal: Medical Image Analysis (2023)

4D flow MRI is an emerging imaging modality that maps voxel-wise blood flow information as velocity vector fields that is acquired in 7-dimensional image volumes (3 spatial dimensions + 3 velocity directions + time). Blood flow in the cardiovascular system is often complex and composite involving multiple flow dynamics and patterns (e.g., vortex flow, jets, stagnating flow) that occur and interact simultaneously. The spectrum of such complex flow dynamics is embedded in the velocity vector field dynamics derived from 4D Flow MRI. However, current flow metrics cannot fully measure high-dimensional vector-field data and embedded complex composite flow data. Instead, these methods need to break down the vector-field data into secondary scalar fields of individual flow components using fluid dynamics operators. These methods are gradient-based and sensitive to data uncertainties, and only focus on individual flow components of the overall composite flow, therefore potentially underestimating the severity of overall flow changes associated with cardiovascular diseases. To address these limitations, in MICCAI 2021, we introduced a novel comprehensive stochastic 4D Flow vector-field signature technique that works directly on the entire spatiotemporal velocity vector field. This technique uses efficient stochastic gradient-free interrogation of multi-million flow vector-pairs per patient to derive the patient's unique flow profile of the complex composite flow alterations and in real-time processing. The signature technique's probabilistic gradient-free formulation should allow for highly robust quantification despite inherent errors in 4D flow MRI acquisitions. Here, we extend the application of the 4D flow vector-field signature technique to the left atrium to analyze complex composite flow changes in patients with atrial fibrillation. In 128 subjects, we performed extensive sensitivity testing and determined that the vector-field signature technique is highly robust to typical sources of data uncertainties in 4D flow MRI: degradation in spatiotemporal resolution, added Gaussian noise, and segmentation errors. We demonstrate the excellent generalizability of the stochastic convergence from the aorta to the left atrium and between different 4D Flow MRI acquisition protocols. We compare the robustness of our technique to existing advanced flow quantification metrics of kinetic energy, vorticity, and energy loss demonstrating a superior performance of up-to 14-fold. Our results show the potential diagnostic and clinical utility of our signature technique in identifying distinctly altered composite flow signatures in atrial fibrillation patients independent of existing flow metrics.
In vitro susceptibility to delafloxacin of Pseudomonas aeruginosa with resistance to other quinolones (ciprofloxacin and levofloxacin)
Authors: J D D Jordán-Chaves, Ruben Lobato-Cano, Javier Casas-Ciria, Carolina Freyre-Carillo, J D Santotoribio, M F de-la-Rubia-Martin
Journal: Clinical Microbiology and Infection (2023)
Diagnostic accuracy of a point-of-care antigen test for SARS-CoV-2 and influenza in a primary care population (RAPTOR-C19)
Authors: Thomas R Fanshawe, Sharon Tonner, Philip J Turner, Jade Cogdale, Margaret Glogowska, Simon de Lusignan, Cecilia Okusi, Rafael Perera, Praveen Sebastianpillai, Alice Williams, Maria Zambon, Brian D Nicholson, F D Richard Hobbs, Gail N Hayward
Journal: Clinical Microbiology and Infection (2023)

Limited evidence exists for the diagnostic performance of point-of-care tests for SARS-CoV-2 and influenza in community healthcare. We carried out a prospective diagnostic accuracy study of the LumiraDx™ SARS-CoV-2 and influenza A or B assay in primary care.
Therapeutic strategies to target connective tissue growth factor in fibrotic lung diseases
Authors: Takuma Isshiki, Safaa Naiel, Megan Vierhout, Kohei Otsubo, Pareesa Ali, Kazuya Tsubouchi, Parichehr Yazdanshenas, Vaishnavi Kumaran, Anna Dvorkin-Gheva, Martin R.J. Kolb, Kjetil Ask
Journal: Pharmacology & Therapeutics (2023)
Biodegradable Osmium Nanoantidotes for Photothermal‐/Chemo‐ Combined Treatment and to Prevent Chemotherapy‐Induced Acute Kidney Injury
Authors: Qi Long, Fangling Liao, Huixi Yi, Mingcheng Wang, Jiani Zhuang, Yue Zheng, Weisheng Guo, Dong‐Yang Zhang
Journal: Advanced Healthcare Materials (2023)

Acute kidney injury (AKI) is a common adverse event in chemotherapy patients. AKI is accompanied by the generation of reactive oxygen species (ROS) and inflammation. Therefore, the management of ROS and inflammation is a potential strategy for AKI mitigation. Herein, polyethylene glycol-coated osmium nanozyme-based antidotes (Os) are developed for imaging-guided photothermal therapy (PTT) in combination with cisplatin (Pt); while, avoiding AKI induced by high-dose Pt. Os nanoantidotes can enhance the efficiency of tumor treatment during combined PTT and chemotherapy and inhibit tumor metastasis by improving the hypoxic and inflammatory tumor microenvironment. Os nanoantidotes preferentially accumulate in the kidney because of their 2-nm size distribution; and then, regulate inflammation by scavenging ROS and generating oxygen to alleviate Pt-induced AKI. Os nanoantidotes can be cleared from the kidneys by urine excretion but can be degraded under hydrogen peroxide stimulation, reducing the bio-retention of these compounds. By integrating PTT with inflammatory regulation, Os nanoantidotes have the potential to reduce the side effects of chemotherapy, offering an alternative route for the clinical management of cancer patients with chemotherapy-induced AKI.
Temporal changes to adult case fatality risk of COVID-19 after vaccination in England between May 2020 and February 2022: a national surveillance study
Authors: Florence Halford, Kathryn Yates, Tom Clare, Jamie Lopez-Bernal, Meaghan Kall, Hester Allen
Journal: Journal of the Royal Society of Medicine (2023)

Risk of death after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has fallen during the pandemic, largely due to immunity from vaccination. In England, the timing and extent of this reduction varied due to staggered eligibility during the primary vaccination campaign, based on age and clinical risk group. Duration of protection is less well understood. Our objective was to estimate the case fatality risk (CFR) by vaccination status and time since last dose during a period of widespread community testing, to better understand the impact of coronavirus disease 2019 (COVID-19) vaccination and duration of protection.
Parkinson’s disease and gut microbiota: from clinical to mechanistic and therapeutic studies
Authors: Xuxiang Zhang, Beisha Tang, Jifeng Guo
Journal: Translational Neurodegeneration (2023)

Parkinson's disease (PD) is one of the most prevalent neurodegenerative diseases. The typical symptomatology of PD includes motor symptoms; however, a range of nonmotor symptoms, such as intestinal issues, usually occur before the motor symptoms. Various microorganisms inhabiting the gastrointestinal tract can profoundly influence the physiopathology of the central nervous system through neurological, endocrine, and immune system pathways involved in the microbiota-gut-brain axis. In addition, extensive evidence suggests that the gut microbiota is strongly associated with PD. This review summarizes the latest findings on microbial changes in PD and their clinical relevance, describes the underlying mechanisms through which intestinal bacteria may mediate PD, and discusses the correlations between gut microbes and anti-PD drugs. In addition, this review outlines the status of research on microbial therapies for PD and the future directions of PD-gut microbiota research.
Adjuvant treatment in renal cell carcinoma: a never-ending story?
Authors: Veronica Mollica, Francesco Massari
Journal: The Lancet (2023)

The CheckMate 914 trial1 assessed the role of nivolumab plus ipilimumab compared with double placebo in the adjuvant setting in patients with localised renal cell carcinoma (RCC). The experimental treatment did not reach its primary endpoint of disease-free survival (DFS) with a hazard ratio (HR) of 0·92 (95% CI 0·71–1·19; p=0·53).
Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consolidative Use of Radiotherapy to Block [CURB] oligoprogression): an open-label, randomised, controlled, phase 2 study
Authors: Chiaojung Jillian Tsai, Jonathan T Yang, Narek Shaverdian, Juber Patel, Annemarie F Shepherd, Juliana Eng, David Guttmann, Randy Yeh, Daphna Y Gelblum, Azadeh Namakydoust, Isabel Preeshagul, Shanu Modi, Andrew Seidman, Tiffany Traina, Pamela Drullinsky, Jessica Flynn, Zhigang Zhang, Andreas Rimner, Erin F Gillespie, Daniel R Gomez, Nancy Y Lee, Michael Berger, Mark E Robson, Jorge S Reis-Filho, Nadeem Riaz, Charles M Rudin, Simon N Powell, Michael Berger, Jacqueline Bromberg, Linda Chen, Chau Dang, Jeeban P Das, Pamela Drullinsky, Julianna Eng, Jessica Flynn, Daphna Y Gelblum, Erin F Gillespie, Jeffrey Girshman, Daniel R Gomez, Ayca Gucalp, David Guttmann, Carla Hajj, Daniel Higginson, Afsheen Iqbal, Atif J Khan, Quincey LaPlant, Nancy Y Lee, Justin M Mann, Shanu Modi, Azadeh Namakydoust, Kenneth Ng, Juber Patel, Simon N Powell, Isabel Preeshagul, Jorge S Reis-Filho, Marsha Reyngold, Nadeem Riaz, Andreas Rimner, Mark E Robson, Charles M Rudin, Rachel Sanford, Andrew D Seidman, Ronak Shah, Narek Shaverdian, Annemarie F Shepherd, Jacob Y Shin, Steven Sugarman, Tiffany A Traina, Chiaojung Jillian Tsai, Abraham J Wu, Amy J Xu, Jonathan T Yang, Randy Yeh, Zhigang Zhang, Wanqing Zhi
Journal: The Lancet (2023)
Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial
Authors: Silvio Danese, Remo Panaccione, Brian G Feagan, Anita Afzali, David T Rubin, Bruce E Sands, Walter Reinisch, Julián Panés, Aparna Sahoo, Natalie A Terry, Daphne Chan, Chenglong Han, Mary Ellen Frustaci, Zijiang Yang, William J Sandborn, Tadakazu Hisamatsu, Jane M Andrews, Geert R D'Haens, Oleksandr Oliinyk, Leonid Bilianskyi, Jadwiga Gniady-Jastrzebska, Robert Petryka, Tomasz Arlukowicz, Piotr Gietka, Marcin Zmudzinski, Syed Mumtaz, Douglas Wolf, Katarzyna Wojcik, George Duvall, Monika Augustyn, Rafal Filip, Dino Tarabar, Alexander Tkachev, Ursula Seidler, Eran Zittan, Juris Pokrotnieks, Oksana Shchukina, Andro Machavariani, Laura Loy, Niazy Abu-farsakh, Pesegova Marina, Slobodan Sreckovic, Martin Laclav, Shu-Chen Wei, Daniel Suiter, Aleksey Borsuk, Xavier Hebuterne, Carsten Buning, Adi Lahat-Zok, Wit Danilkiewicz, Bernadetta Frysna, Ivana Jovicic, Olena Datsenko, Maninder Guram, Animesh Jain, Zahid Rashid, Sonja Heeren, Natallia Shulga, Ivan Timkin, Srdjan Gornjakovic, Milan Lukas, Romain Altwegg, Ariadne Desjeux, Jean-Marie Reimund, Manana Giorgadze, Christoph Jochum, Hiroaki Ito, Katsuhiko Nakai, Tomohisa Takagi, Osamu Zaha, Changhwan Choi, Taeoh Kim, Jonghun Lee, Ieva Stundiene, Ida Normiha Hilmi, Rosaida Hj Md Said, Jaroslaw Leszczyszyn, Diana Abdulganieva, Yulia Fominykh, Svetlana Maksyashina, Jozef Balaz, Manuel Van Domselaar, Taylan Kav, Patrick Dennis, Patricia Henry, Robert Holmes, Christopher Johnson, Matthew McBride, Harry Sarles, Gregory Moore, Ruslan Yakubtsevich, Vinciane Muls, Stevan Trbojevic, Waqqas Afif, Charles Bernstein, Ivo Klarin, Zuzana Serclova, Miroslava Volfova, Pierre Desreumaux, Cyrielle Gilletta de Saint Joseph, Xavier Roblin, Lucine Vuitton, Kakhaber Chelidze, Tanja Kuehbacher, Ioannis Koutroubakis, Michele Cicala, Walter Fries, Antonio Gasbarrini, Nobuo Aoyama, Yoshito Hayashi, Fumihito Hirai, Norkiyuki Horiki, Namiko Hoshi, Tomoki Inaba, Ishida Hiroyasu, Atsuo Maemoto, Takayuki Matsumoto, Kayoko Matsushima, Satoshi Motoya, Masaki Taruishi, Mohammed Rashid, Jaeyoung Chun, Young-Ho Kim, Dong Il Park, Ala Sharara, Laimas Jonaitis, Gjorgi Deriban, James Brooker, Beata Gawdis-Wojnarska, Barbara Wozniak-Stolarska, Pavel Andreev, Vladimir Simanenkov, Vasiliy Trofimov, Igor Jovanovic, Natasa Zdravkovic, Xavier Aldeguer i Mante, Vicent Hernandez Ramirez, Hale Akpinar, Gurkan Celebi, Hulya Hamzaoglu, Juan Fernandez, Jayaprakash Kamath, Nicole Palekar, Jatinder S. Pruthi, David Rausher, Timothy Ritter
Journal: The Lancet. Gastroenterology & hepatology (2023)
Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline–trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial
Authors: Inder Kaul, Sharon Sawchak, Christoph U Correll, Rishi Kakar, Alan Breier, Haiyuan Zhu, Andrew C Miller, Steven M Paul, Stephen K Brannan
Journal: The Lancet (2023)
Virus-containing migrasomes enable poxviruses to evade tecovirimat/ST-246 treatment
Authors: Wenbo Zhao, Xichi Tang, Leiliang Zhang
Journal: Journal of Infection (2023)

•Tecovirimat/ST-246 didn’t block migrasomes formation induced by VACV •Migrasomes contain VACV virons in the presence of tecovirimat •Poxvirus could be transmitted through migrasomes in the presence of tecovirimat •Tecovirimat treatment could not completely stop mpox
High-resolution CT phenotypes in pulmonary sarcoidosis: a multinational Delphi consensus study
Authors: Sujal R Desai, Nishanth Sivarasan, Kerri A Johannson, Peter M George, Daniel A Culver, Anand Devaraj, David A Lynch, David Milne, Elisabetta Renzoni, Hilario Nunes, Nicola Sverzellati, Paolo Spagnolo, Robert P Baughman, Ruchi Yadav, Sara Piciucchi, Simon L F Walsh, Vasileios Kouranos, Athol U Wells, Adam Anderson, Adam Morgenthau, Adrian Gaser, Alexander Vizel, Alexandra Speranskaya, Alicia Gerke, Altinisik Goksel, Alvaro Undurraga, Amita Sharma, Andrea Oh, Ann Leung, Anna Rita Larici, Antje Prasse, Antonietta Mazzei, Antonio Morais, Ashu Bhalla, Belen Del Rio, Bhavin Jankharia, Brett Elicker, Carlos Pereira, Catherine Biegelman-Aubry, Charles White, Claudia Ravaglia, Connie Hsia, Cornelia Schaefer-Prokop, David Launay, Deepak Talwar, Diego Castillo, Divya Patel, Dominique Israel-Biet, Dominique Valeyre, Edward James Britt, Elena Bargagli, Elisabeth Bendstrup, Elliott Crouser, Esther Nossent, Eugeny Shmelev, Eva Carmona Porquera, Francesco Bonella, Fleur Cohen-Aubart, Florence Jeny, Giovanni Ferrara, Gong Yong Jin, Hasti Robbie, Helmut Prosch, Hiromitsu Sumikawa, Ho Ling-Pei, Ho Yun Lee, Irina Strambu, Ivette Buendia-Roldan, Jan Grutters, Jay Ryu, Jeff Swigris, Jelle Miedema, Jin Mo Goo, Joseph Barnett, Johny Verschakelen, Jonathan Goldin, Joon Beom Seo, Juan Enghelmayer, Juan Mana, Juergen Behr, Karen Patterson, Katerina Antoniou, Kevin Brown, Kiminori Fujimoto, Laurent Savale, Lisa Maier, Luca Richeldi, Manuel Lessa Ribeiro Neto, Marc Humbert, Marc Judson, Marcel Veltkamp, Margaret Wilsher, Maria Molina, Maria Otaola, Marie-Pierre Revel, Mario Silva, Marjolein Drent, Mark Schiebler, Marlies Wijsenbeek-Lourens, Martina Bonifazi, Martine Remy-Jardin, Matthew Koslow, Meyer Balter, Michael Kreuter, Muhunthan Thillai, Nabeel Hamzeh, Nazia Chaudhuri, Nesrin Mogulkoc, Nevins Todd, Nick Screaton, Nicole Goh, Nirav Shah, Ogugua Obi, Oksana Shlobin, Olga Baranova, Paul Bresser, Paula Rottoli, Pierre-Yves Brillet, Qonita Said-Hartley, Raphael Borie, Remy Mostard, Richard van Zyl-smit, Ronaldo Kairalla, Ryoko Egashira, Samia Boussouar, Sang Min Lee, Sanjeev Bhalla, Sara Tomassetti, Silvia Quadrelli, Simon P Hart, Sonye Danoff, Sujeet Rajan, Sun Mi Choi, Susan Copley, Tae Jung Kim, Takeshi Johkoh, Tamera Corte, Theresa McLoud, Thomas Wessendorf, Tiago Alfaro, Toru Arai, Ulrich Costabel, Vanesa Vicens-Zygmunt, Venerino Poletti, Vincent Cottin, Violeta Vucinic, Wim Wuyts, Wouter van Es, Yeon Joo Jeong, Yoshikazu Inoue
Journal: The Lancet Respiratory Medicine (2023)